Drug Trial Radar · NCT00587015
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
Last checked: Nov 20, 2026Latest source record: Nov 22, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 2007
Primary completion
Mar 2008
Study completion Oct 2009
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.
Conditions
- Lymphoma
Interventions
CAT-8015Drug
The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess safety, estimate MTD, characterize toxicity profile, study pharmacology and observe anti-tumor activity at the MTD.Time frame: Day 28
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Tower Hematology Oncology Medical Group
Beverly Hills, California
NCI, National Institutes of Health
Bethesda, Maryland
Kalinika Hemotologii Uniwersytetu Medycznego
Lodz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.